

MANUFACTURERS OF BULK DRUGS & DEALERS OF CHEMICALS & SOLVENTS

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

30th May'2016

To, Dept. of Corporate Services The Bombay Stock Exchange Ltd 1st floor, Rotunda Building, M.S.Marg, Mumbai-400 001.

Sub: AUDITED RESULT FOR THE QUARTER & YEAR ENDED . 31st MARCH'2016

Dear Sir,

Pursuant to listing agreement we are enclosing herewith the Audited financial results for the quarter and year ended 31st March,2016 with Auditor's Report.

Kindly acknowledge the same & oblige.

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

Managing Director

Encl.: a/a



MANUFACTURERS OF BULK DRUGS & **DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. (022) 66312998 / 66154219 Fax: 66154219 E-mail: info@aareydrugs.com REGD. OFF. & FACTORY: E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 (02525) 271049 E-mail: corporate@aareydrugs.com Web: www.aareydrugs.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH' 2016

						₹ In Lacs
Sr No.	PARTICULARS	3 MONTHS ENDED			YEAR ENDED	
		31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
		Audited	Unaudited	Audited	Audited	Audited
1	Net Income from Sales/Services	10863.49	6333.07	7719.02	24602.87	0434444
2	Cost of Sales/Services	10740.46	6308.36	7713.02	24267.08	21344,14 20967,17
_	Increase/Decrease in stock in	10740.40		7731.02	24207.00	20907.17
	trade & work in progress					
	b. Consumption of Raw Materials					
_	c. Purchase of traded goods					
	d. Other Expenditure					
3	Gross Profit (1-2)	123.03	24.71	-12.50	335.79	
4	General Administrative Expenses	48.96	29.05	71.94	192.16	376.97
5	Selling and Distribution Expenses	5.46	26.02		55.42	220.59
6	Depreciation	-4.17	20.02	11.18 62.79	61.89	46.09 105.33
7	Operating Profit before Interest (3) -	72.78	-52.67	-158.41	26.32	4.96
	(4+5+6)					
8	Interest	42.97	40.28	38.36	158.71	123.07
9	Exceptional Items	0	0	0	0	0
10	Operating Profit after Interest and Exceptional Items (7-8-9)	29.81	-92.95	-196.77	-132.39	-118.11
11	Other Income	26.12	113.02	237.42	313.69	259.11
12	Profit (+)/Loss (-) from Ordinary Activities before tax (10+11)	55.93	20.07	40.65	181.30	141.00
13	Tax Expenses	52.36	0.00	32.16	52.36	32.16
14	Net Profit (+)/Loss (-) from ordinary	3.57	20.07	8.49	128.94	108.84
17	Activities after tax (12-13)	0.07	20.07	0.45	120.54	105.04
15	Extraordinary items (net of tax expenses)	0	0	0	0	0
16	Net Profit(+)/Loss(-) for the period(14-15)	3.57	20.07	8.49	128.94	108.84
17	Paid-up equity share capital-Rs.10/-	1681.4684	1681.4684	1681.4684	1681.4684	1681.4684
18	Reserves excluding revaluation reserves(as per balance sheet) of previous accounting year to be given in column (5)	1001.4004	1001.4004	1001,4004	1001.4004	1001.4034
	Earning Per Share (EPS) a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.02	0.12	0.05	0.77	0.65
20	Public shareholdingNumber of sharesPercentage of Shareholding	7157132 42.56%	7160132 42.58%	7160143 42.58%	7157132 42.56%	7160143 42.58%





MANUFACTURERS OF BULK DRUGS & DEALERS OF CHEMICALS & SOLVENTS

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © ; (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

21	Promoters and promoter group					
	Shareholding **					
	a) Pledged/Encumbered					
	Number of Shares	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of		21 33			
	the total shareholding of promoter &					
	promoter group)					
	Percentage of shares (as a% of	NIL	NIL	NIL	NIL	NIL
	the total share capital of the company)					
	b) Non-encumbered					
	Number of Shares	9657552	9654552	9654541	9657552	9654541
	Percentage of Shares (as a% of	100.00%	100.00%	100.00%	100.00%	100.00%
	the total shareholding of promoter &					
	promoter group)					
	Percentage of shares (as a % of	57.44%	57.42%	57.42%	57.44%	57.42%
	the total share capital of the company)					

Notes :-

- The above financial results have been taken on record by the Board of Director's of the Company at its Board meeting held on 30.05.2016
- Status of investors complaints (Nos): Opening Balance as on 01.01.16 NIL; Received during the quarter - 1; Disposed off during the quarter - 1; Closing Balance as on 31.03.16 - 0

Place : Tarapur

Date : 30th May 2016

By Order of the Board of Directors

Mihir R.Ghatalia Managing Director

For AAREY DRUGS & PHARMACEUTICALS LTD.

MANAGING DIRECTOR

DMKH & CO.

Chartered Accountants

803/804, Ashok Heights, Opp Saraswati Apartment, Nikalaswadi Road, Near Bhuta School, Old Nagardas X Road, Gundavali, Andheri (East), Mumbai -400092

+91-2226824800/4900

+91-2226824800/4900

Email ID:-dmkhco@gmail.com



Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
Board of Directors of
AAREY DRUGS AND PHARMACEUTICALS LIMITED.

We have audited the quarterly financial results of AAREY DRUGS AND PHARMACEUTICALS LIMITED, for the quarter ended 31st March 2016 and the year to date results for the period 1st April 2015 to 31st March 2016, attached herewith, being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management.

Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- II. give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31st March 2016 as well as the year to date results for the period from 1st April 2015 to 31st March 2016.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For DMKH & Co,

Chartered Accountant

FRN: 116886W

CA. Manish Kankan

Partner

M.No. 158020 Place: Mumbai

Date: 30th May, 2016

Branch Office:- 4, AKSHAY APARTMENT, DAMLE MARG, RAMDAS PETH AKOLA- 444001, MAHARASHTRA